EBV specific CTL: A model for immune therapy

Cliona M. Rooney; H. E. Heslop; M. K. Brenner

doi:10.1111/j.1423-0410.1998.tb05463.x

EBV specific CTL: A model for immune therapy

Cliona M. Rooney, H. E. Heslop, M. K. Brenner

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

We have been generating Epstein-Barr virus specific cytotoxic T cells for patients at high risk of developing EBV driven lymphoma. To discover the fate of the cells in vivo, we first marked them genetically, using a retroviral vector. Our results in 51 patients show that the approach is safe, that the CTL persist for several years and that they are able to mediate anti-viral and anti-tumor effects. We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value.

Original language	English (US)
Pages (from-to)	497-498
Number of pages	2
Journal	Vox Sanguinis
Volume	74
Issue number	SUPPL. 2
DOIs	https://doi.org/10.1111/j.1423-0410.1998.tb05463.x
State	Published - 1998

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/j.1423-0410.1998.tb05463.x

Cite this

@article{6d02a71780034172823052cbffb73e50,

title = "EBV specific CTL: A model for immune therapy",

abstract = "We have been generating Epstein-Barr virus specific cytotoxic T cells for patients at high risk of developing EBV driven lymphoma. To discover the fate of the cells in vivo, we first marked them genetically, using a retroviral vector. Our results in 51 patients show that the approach is safe, that the CTL persist for several years and that they are able to mediate anti-viral and anti-tumor effects. We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value.",

author = "Rooney, {Cliona M.} and Heslop, {H. E.} and Brenner, {M. K.}",

year = "1998",

doi = "10.1111/j.1423-0410.1998.tb05463.x",

language = "English (US)",

volume = "74",

pages = "497--498",

journal = "Vox Sanguinis",

issn = "0042-9007",

publisher = "Wiley",

number = "SUPPL. 2",

}

TY - JOUR

T1 - EBV specific CTL

T2 - A model for immune therapy

AU - Rooney, Cliona M.

AU - Heslop, H. E.

AU - Brenner, M. K.

PY - 1998

Y1 - 1998

N2 - We have been generating Epstein-Barr virus specific cytotoxic T cells for patients at high risk of developing EBV driven lymphoma. To discover the fate of the cells in vivo, we first marked them genetically, using a retroviral vector. Our results in 51 patients show that the approach is safe, that the CTL persist for several years and that they are able to mediate anti-viral and anti-tumor effects. We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value.

AB - We have been generating Epstein-Barr virus specific cytotoxic T cells for patients at high risk of developing EBV driven lymphoma. To discover the fate of the cells in vivo, we first marked them genetically, using a retroviral vector. Our results in 51 patients show that the approach is safe, that the CTL persist for several years and that they are able to mediate anti-viral and anti-tumor effects. We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value.

UR - http://www.scopus.com/inward/record.url?scp=0031849017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031849017&partnerID=8YFLogxK

U2 - 10.1111/j.1423-0410.1998.tb05463.x

DO - 10.1111/j.1423-0410.1998.tb05463.x

M3 - Article

C2 - 9704488

AN - SCOPUS:0031849017

SN - 0042-9007

VL - 74

SP - 497

EP - 498

JO - Vox Sanguinis

JF - Vox Sanguinis

IS - SUPPL. 2

ER -

EBV specific CTL: A model for immune therapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this